Modern Citrus Pectin

Attaches to Galectin-3, Abnormally High in Cancers, to Prevent Tumor Cells From Binding

Modern Citrus Pectin Healthy Living Magazine

Modern Citrus Pectin Healthy Living Magazine

The American Cancer Society (ACS) provides a cautious review on modified citrus pectin’s early signs of ability to stop the spread of cancer tumors in experimental studies and uncontrolled human trials.

Why Citrus Pectin Is Modified

Modified citrus pectin (MCP) has been altered so that it can be more easily absorbed by the digestive tract. Pectin is a carbohydrate that is made of hundreds or thousands of sugar molecules chemically linked together. It is found in most plants and is particularly plentiful in the peels of apples, citrus fruits and plums. In modified citrus pectin the pectin has been chemically altered to break its molecules into smaller pieces. Pectin in its natural form cannot be absorbed by the body and is considered a type of soluble dietary fiber, whereas modified pectin can be absorbed into the bloodstream.

MCP And Galectin-3

MCP appears to attach to galectin-3, a common chemical in many cells. Galectin-3 is present in abnormally high levels in many cancers and is believed to contribute to the growth, survival and spread of cancer cells, as well as the processes of chronic inflammation and fibrosis (uncontrolled scar tissue build-up). A fast-growing body of published data now demonstrates the links between excess galectin-3 and heart disease, kidney injury, arthritis and other pro-inflammatory conditions.

Armes Immune Cells As Superior KillERS

MCP is richer than ordinary pectin in unsaturated oligogalacturonic acids, carbohydrates immune cells feed on, turning them into superior killers, stopping the cancer’s invasion of neighboring tissues.

Reduces Tumor Spread

In the March 2013 Integrative Cancer Therapies, Indiana University researchers studied MCP for men’s and women’s cancers in the test tube combined with BreastDefend and ProstaCaid, commercial formulas supplying anticancer botanicals such as mushrooms and BCM-95 curcumin. With breast and prostate cancer, MCP-based combinations, even if not outright killers, countered the lethality of cell migration.

Cancer Society Cites MCP Research

According to the ACS, “Several animal studies found that MCP helped reduce the spread of prostate, breast, and skin cancer. Animals with these types of cancer that were fed MCP had a much lower risk of the tumor spreading to the lungs. For example, one study examined the effects of MCP on lung metastases from melanoma cells. Researchers injected mice with melanoma cells. In the mice that were also given MCP, significantly fewer tumors spread to the lungs than in the mice that did not receive the compound. When lung tumors did develop in the mice treated with MCP, the tumors tended to be smaller than those formed in untreated animals. These studies appear to show that MCP makes it difficult for cancer cells that break off from the main tumor to join together and grow in other organs.” In one published clinical trial, 10 men with prostate cancer were treated with PectaSol-C® MCP after standard treatment failed. In seven of these men, blood tests found prostate specific antigen (PSA, a marker of prostate cancer growth). Their PSA doubling time (a measure of how fast PSA goes up) improved in comparison with measurements done before taking MCP, indicating that MCP may have a slowing effect on the cancer’s growth. “This study had no control group (a group of men who did not take MCP), which limits the strength of its conclusions on MCP’s effectiveness. It also did not measure survival or other important endpoints. However, taken with the information gained from animal studies, it suggests that MCP may have a role in reducing the growth and spread of cancer.”

74% Reduction In Toxic Metals

MCP reduces the body’s burden of chemical toxins linked with cancer, including arsenic. A study published by Dr. Isaac Eliaz (the developer of PectaSol-C® Modified Citrus Pectin) in the October 2006 issue of Phytotherapy Research, reported that MCP administration increased the urinary excretion of arsenic by 130%; cadmium by 150% and lead by 560%. Dr Eliaz developed PectaSol-C® in 1995 to address cancer and heavy metal toxicity in his clinical practice. In five case studies reduction in toxic heavy metals (74% average decrease) was achieved without side effects with the use of MCP alone versus an MCP/alginate combination. “The gradual decrease of total body heavy metal burden is believed to have effect in each patient’s recovery and health condition. This is the first known documentation of evidence of such results in a clinical report of case studies with possible correlation between clinical outcome and a reduction in toxic heavy metal load in patients using MCP and/or an MCP/ alginate complex.”

References
Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytother Res. 2006 Oct;20(10):859-864. Eliaz I, Weil E, Wilk B. Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification--five case reports. Forsch Komplementmed. 2007 Dec;14(6):358- 364. doi: 10.1159/0000109829. E-pub 2007 Dec 12. Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301-304. Jiang J, Eliaz I, Sliva D. Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells. Integr Cancer Ther. 2013 Mar;12(2):145-152. doi: 10.1177/1534735412442369. E-pub 2012 Apr 24. Ramachandran C, Wilk BJ, Hotchkiss A, Chau H, Eliaz I, Melnick SJ. Activation of human T-helper/ inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complement Altern Med. 2011 Aug 4;11:59. doi: 10.1186/1472-6882-11-59. Yan J, Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and- independent prostate cancer cells. Integr Cancer Ther. 2010 June;9(2):197-203. doi: 10.1177/1534735410369672. E-pub 2010 May 11. Zhao ZY, Liang L, Fan X, Yu Z, Hotchkiss AT, Wilk BJ, Eliaz I. The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Altern Ther Health Med. 2008 July-Aug;14(4):34-38.
comments powered by Disqus